Walgreens Credit Rating & NNN Cap Rate

Walgreens Business Overview & NNN Investment Profile

Walgreens Boots Alliance went private on August 28, 2025, when Sycamore Partners completed a $10B acquisition, taking the company private after approximately 100 years as a public company. The company operates 7,500 U.S. pharmacy locations following recent store closures and now stands under private equity ownership focused on operational restructuring. CRITICAL: Walgreens does NOT meet investment-grade NNN criteria and falls BELOW the BBB‑/Baa3 threshold required for investment-grade portfolio allocations. Pre-privatization, Walgreens held ratings of Ba3/BB‑, which were non-investment-grade, and ratings have been withdrawn as the company is now private.

Following privatization, Walgreens was split into five separate business entities: Walgreens (retail pharmacy), The Boots Group (UK pharmacy), Shields Health Solutions (pharmacy benefits manager), CareCentrix (home healthcare), and VillageMD (primary care clinics). The company announced a store closure program encompassing 1,200 pharmacy locations over three years (500 closures in FY2025), representing significant operational and credit deterioration. For NNN investors, Walgreens presents elevated NNN lease risk due to privatization, high leverage, and ongoing store closures. The company’s long 25-year lease terms provide some landlord protections, but credit concerns and bankruptcy risk flagged by analysts represent material concentration risks.

Walgreens’ financial profile has deteriorated markedly. Pre-privatization debt exceeded $10B, and Sycamore Partners’ acquisition included significant new leverage for the buyout. Management’s store closure program and operational restructuring signal sustained profitability challenges. For NNN investors holding Walgreens properties, careful evaluation of refinance/exit strategies is prudent given the elevated credit risk profile and lack of public ratings transparency.

Walgreens Credit Rating Analysis

Walgreens ratings have been withdrawn by credit rating agencies following the company’s privatization on August 28, 2025. Prior to privatization, Walgreens held an S&P rating of BB‑ with stable outlook and Moody’s rating of Ba3 with stable outlook, both non-investment-grade. The privatization by Sycamore Partners introduced significant new leverage and financial restructuring risk, with the company now split into five separate business entities under PE ownership.

Walgreens falls BELOW investment-grade thresholds and is NOT suitable for core investment-grade NNN portfolios. The company’s operating challenges include declining comparable sales, increased competition from Amazon pharmacy services and mail-order options, labor unionization at retail locations driving wage inflation, and the planned closure of 1,200 stores (representing 12-13% of the base). Analysts have flagged bankruptcy risk as a potential outcome if the company fails to stabilize operations and manage debt levels under Sycamore’s ownership.

Primary risks include continued same-store sales decline, Amazon and mail-order pharmacy disruption, labor cost inflation, physician-aligned retail clinic competition, and debt service stress under Sycamore Partners’ high-leverage structure. The 1,200-store closure program over three years represents approximately 500 closures in FY2025 plus prior closures, materially reducing the store base and cash generation capacity. Credit improvement likelihood is low to moderate without substantial operational restructuring and revenue stabilization.

Walgreens NNN Lease Structure

Walgreens NNN leases typically feature 25-year initial terms (among the longest in retail), providing investors with exceptional lease income visibility but also extending exposure to the company’s ongoing credit deterioration. The company provides corporate guarantees, though the value of these guarantees has diminished significantly following privatization. Annual rent escalations typically include flat initial periods followed by bumps at renewal, creating less predictable escalation compared to percentage-of-sales or fixed-percentage models.

Typical Walgreens properties occupy large 12,000-14,500 square feet on 1.5-2.0 acres, reflecting the full-service pharmacy model with drive-thru, clinical services, and expanded merchandise (health/beauty, convenience). The large footprint creates landlord challenges if Walgreens fails or closes the location, as alternative uses for the space may be limited and conversion costs can be significant. Many Walgreens locations have limited co-tenancy, making the property heavily dependent on Walgreens’ continued operation.

Lease structures often include percentage rent provisions tied to pharmacy sales and health services revenue, which have declined materially in recent years. Break options tied to store closure or bankruptcy proceedings may be available in some leases negotiated post-2020. Given Walgreens’ financial distress, landlords should carefully review lease documentation for default remedies and creditor protections.

Walgreens NNN Cap Rate & Pricing Trends

Walgreens NNN properties currently trade at cap rates between 8.6% and 9.5%, reflecting the company’s below-investment-grade (non-rated) status, privatization uncertainty, and significant credit risk premium. These elevated cap rates represent substantial investor compensation for credit and refinance risk. Pricing for individual properties typically ranges from $2.5 million to $6.0 million, though recent sales have demonstrated significant price volatility as investors reassess credit quality post-privatization.

The Walgreens NNN market experienced severe repricing following the privatization announcement and completion, as credit ratings were withdrawn and bankruptcy concerns surfaced. The investment grade guide explicitly excludes Walgreens due to below-threshold credit quality. Recent transaction volume has declined materially as institutional investors have withdrawn demand, leaving primarily distressed/special situations players and value-add managers active in the market.

Mortgage lender appetite has dried up significantly, with most traditional lenders now declining Walgreens collateral or substantially increasing leverage restrictions (LTV requirements). Refinance windows are materially constrained, and some landlords have faced challenges extending maturities. Liquidation or distressed sale may be necessary for holders unable to extend maturity or maintain leverage compliance on existing debt.

Walgreens Real Estate Footprint

Walgreens operates 7,500 U.S. pharmacy locations as of FY2025 (down from ~8,500 in prior periods) following store closure announcements and planned exits. The company’s footprint emphasizes high-traffic corner locations and shopping center anchor positions, with particularly strong density in urban and suburban markets. The closure program targeting 1,200 locations over three years (500 in FY2025 plus ongoing closures) signals continued portfolio contraction and operational retrenchment.

Walgreens real estate strategy has shifted toward closing underperforming locations, consolidating pharmacy services to fewer, higher-productivity stores, and partnering with primary care providers (VillageMD) in select locations. The large-format properties create redevelopment challenges and limited alternative use options for landlords if Walgreens exits.

Walgreens Growth & Expansion Outlook

Walgreens’ growth outlook is significantly constrained. The company is in a store closure and operational restructuring phase rather than expansion mode. The 1,200-store closure program over three years represents approximately 12-13% of the base and prioritizes unprofitable and/or redundant locations. Management’s focus is stabilizing the core pharmacy business, managing debt levels under Sycamore ownership, and exploring strategic partnerships (primary care clinics, health services expansion).

The five-company split structure creates operational complexity and uncertainty regarding capital allocation priorities and financial stability of each entity. Walgreens retail pharmacy operations face sustained Amazon and mail-order competition, union pressures, and consumer behavior shifts toward digital health and convenience alternatives. Long-term viability of the current store base is uncertain, and further closures are possible beyond the announced 1,200-store program.

Walgreens NNN Investment: Pros & Cons

Comparable NNN Tenants

Frequently Asked Questions